Improving drug delivery to enhance treatment for shoulder contracture
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation
['FUNDING_R01'] · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · NIH-10894132
This study is looking at a new way to deliver treatments for shoulder contracture, a condition that makes it hard to move your shoulder, using a natural hormone and a common medication to help improve your movement and tackle the problem at its source.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10894132 on ClinicalTrials.gov |
What this research studies
This research investigates a new method for delivering biotherapeutics that can improve their effectiveness by increasing the presence of specific receptors in the body. It focuses on the use of relaxin-2, a natural peptide hormone, and dexamethasone to treat shoulder contracture, a condition that limits joint movement. By enhancing the delivery and concentration of these treatments, the goal is to restore joint range of motion and address the underlying causes of the condition. Patients may benefit from a more effective treatment that targets the root of their symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients experiencing shoulder contracture or related joint mobility issues.
Not a fit: Patients with conditions unrelated to shoulder contracture or those who do not have the specific receptors targeted by the treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from shoulder contracture, improving their mobility and quality of life.
How similar studies have performed: Other research has shown promise in using advanced drug delivery systems to enhance therapeutic efficacy, suggesting a potential for success in this approach.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRINSTAFF, MARK W. — BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
- Study coordinator: GRINSTAFF, MARK W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.